SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 211 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 3.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,977,065 | -64.7% | 71,711 | -61.5% | 0.09% | -63.8% |
| Q2 2023 | $5,601,944 | +145.9% | 186,359 | +196.4% | 0.26% | +129.5% |
| Q1 2023 | $2,277,844 | +2.2% | 62,872 | +0.6% | 0.11% | -0.9% |
| Q4 2022 | $2,229,901 | +154.8% | 62,515 | +141.9% | 0.11% | +135.4% |
| Q3 2022 | $875,000 | -21.7% | 25,842 | -33.2% | 0.05% | -18.6% |
| Q2 2022 | $1,118,000 | -51.4% | 38,667 | -45.7% | 0.06% | -44.3% |
| Q1 2022 | $2,300,000 | +8.0% | 71,159 | -2.5% | 0.11% | +15.2% |
| Q4 2021 | $2,129,000 | +1.1% | 73,004 | -7.5% | 0.09% | -7.1% |
| Q3 2021 | $2,105,000 | -18.2% | 78,915 | -5.6% | 0.10% | -17.5% |
| Q2 2021 | $2,573,000 | +16.4% | 83,570 | -1.1% | 0.12% | +10.1% |
| Q1 2021 | $2,211,000 | -14.3% | 84,464 | -17.6% | 0.11% | -22.7% |
| Q4 2020 | $2,579,000 | -42.9% | 102,502 | -52.7% | 0.14% | -49.6% |
| Q3 2020 | $4,517,000 | +14.6% | 216,713 | +30.6% | 0.28% | +9.4% |
| Q2 2020 | $3,942,000 | – | 165,977 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 335,000 | $8,934,000 | 13.38% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,016,665 | $27,114,000 | 2.46% |
| Bruce & Co., Inc. | 402,105 | $10,724,000 | 2.28% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $7,934,000 | 1.91% |
| ARMISTICE CAPITAL, LLC | 3,900,000 | $104,013,000 | 1.76% |
| Bridge City Capital, LLC | 108,884 | $2,904,000 | 1.32% |
| S&T BANK/PA | 316,098 | $8,430,000 | 1.31% |
| Kent Lake Capital LLC | 100,000 | $2,667,000 | 1.15% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 331,140 | $8,832,000 | 1.02% |
| Prairiewood Capital, LLC | 45,297 | $1,208,000 | 0.99% |